Search
forLearn
5 / 801 resultslearn ACETYL TETRAPEPTIDE-2
learn oligopeptide-71
learn sh-Polypeptide-7
learn Beta Polypeptide
Research
5 / 127 results
research Identification of transcriptional targets of Wnt/β-catenin signaling in dermal papilla cells of human scalp hair follicles: EP2 is a novel transcriptional target of Wnt3a
Wnt3a activates certain genes in hair follicle cells, including a newly discovered one, EP2, which may affect hair growth.
research Prostanoid receptors in anagen human hair follicles
Human hair follicles contain a complex network of prostanoid receptors that may influence hair growth.
research Understanding the role of prostaglandin E2 in regulating human platelet activity in health and disease
Prostaglandin E2 affects human platelet activity in complex ways that could lead to personalized heart disease treatments.
research Human Scalp Hair Follicles Express Prostaglandin E2 Lipid Mediator and Receptors For Pge2
Human scalp hair follicles have PGE2 and its receptors, which might affect hair growth.
research Prostaglandin E 2 Receptor 2 Modulates Macrophage Activity for Cardiac Repair
EP 2 receptor is essential for heart repair by helping macrophages work properly.
Community Join
5 / 1000+ resultscommunity Is it ok to take Xeljanz (A jak inhibitor) while taking finasteride?
The conversation is about whether it is safe to take Xeljanz, a JAK inhibitor, while also taking finasteride for hair loss. The concern is that Xeljanz weakens the immune system, which could be risky.
community Pelage have presented only phase 2a. The rest of phase 2 for PP405 will be presented at a later medical meeting
PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.
community Setipiprant/PGE2 feedbacks?
community Before and after PP405 from phase 2a after applying it for just 4 weeks
community ICYMI: Eirion ET-02’s Successful Phase 1 Trial Results for Androgenic Alopecia Treatment
ET-02 showed significant hair growth in five weeks, outperforming minoxidil, with a non-hormonal mechanism that avoids side effects of treatments like finasteride. A phase 2 trial is planned to further assess ET-02's efficacy and safety.